.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Evolving Treatment Approaches After Checkpoint Inhibition in Advanced Melanoma

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss novel treatment approaches in advanced melanoma after checkpoint inhibition.

EP. 1: Treatment Challenges After Immunotherapy in Advanced Melanoma

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss unmet needs in advanced melanoma after checkpoint inhibition.

EP. 2: The Role of Interventional Radiologists in Advanced Melanoma Management

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss the role of interventional radiologists in melanoma management.

EP. 3: The Promise of Oncolytic Viruses in Advanced Melanoma

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, dive into research behind oncolytic viruses in advanced melanoma.

EP. 4: Data for RP1 Plus Nivolumab in Metastatic Melanoma After Prior PD-1 Inhibition

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, break down data from the IGNYTE trial of RP1 plus nivolumab in advanced melanoma after PD-1 inhibition.

EP. 5: Where RP1 Plus Nivolumab Could Fit in the Treatment Paradigm for Advanced Melanoma Post–PD-1 Inhibition

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss where RP1 plus nivolumab could fit in the advanced melanoma treatment paradigm.

EP. 6: Key Areas of Future Research in Advanced Melanoma

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss ongoing research to watch in advanced melanoma.